HER2/neu intragenic kinase domain mutations may be major determinant of response to trastuzumab or specific kinase inhibitors in non-small cell lung cancer patients | AVESİS

Hacettepe University Research Information System

HER2/neu intragenic kinase domain mutations may be major determinant of response to trastuzumab or specific kinase inhibitors in non-small cell lung cancer patients

Copy For Citation

Altundag O., Altundag K., Ozcakar B., Silay Y.

LUNG CANCER, vol.49, no.2, pp.279-280, 2005 (SCI-Expanded)

Publication Type: Article / Letter
Volume: 49 Issue: 2
Publication Date: 2005
Doi Number: 10.1016/j.lungcan.2005.02.013
Journal Name: LUNG CANCER
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.279-280
Hacettepe University Affiliated: No